The Financial Half-Life: The Reimbursement Cliff in Radiopharma
The consensus story in radiopharma is a supply story, and it is true. This report follows the money instead: where the surplus actually lands, who carries the risk to earn it, and what happens to a decentralised treatment network when the billing rules that subsidise it change.
What this report answers
- If the science and the clinical work sit in one place, why does the margin end up somewhere else?
- What does a decaying, six-figure dose do to a billing system built for durable goods?
- How have supply and isotope contracts been rewritten, and in whose favour?
- What happens to community treatment access when a reimbursement subsidy is withdrawn?
- Which capital and talent positions are exposed if care re-centralises into academic hubs?
- What signals would confirm or break the thesis over the next twelve months?
What the analysis establishes
Two clocks, not one
The report sets out a second clock running alongside the physical half-life everyone already watches, and argues it is the one almost nobody is pricing. The opening parts state the resulting inversion plainly: the parties absorbing the clinical, financial and regulatory risk are not the parties capturing the margin.
Where the upstream margin is contracted
A part on supply contracting shows how the bargaining table has flipped, tracing the shift in what a sponsor now commits to and how far ahead. It works through named agreements across manufacturing slots and isotope offtake, and identifies who ends up holding volume risk when a programme stalls.
The downstream billing mechanics
The report moves to the hospital side and examines the arbitrage and workload-accounting mechanics that decide whether a site can afford to deliver a therapy at all. This is the part it argues capital allocators skip, because it requires reading medical billing rather than clinical data.
What it does to capital and to people
Two parts read the consequences through the investment case and through the workforce, covering which roles and which infrastructure positions gain or lose if the delivery model re-centralises. The argument connects a billing rule to a staffing and siting decision rather than treating them separately.
The arithmetic read forward
A later part puts both clocks together and works the arithmetic forward rather than describing it. It is followed by a set of tripwires: specific, checkable events over the following twelve months that would confirm the thesis or break it, which is how the report invites you to test it.
Where value should sit
The closing part states where the report believes value, talent and capital should be positioned given everything preceding it. It is written as a position rather than a survey, and the report is explicit that its forward-looking sections are scenario analysis built on proposed rules, not statements of fact.
How it was built
A financial and regulatory read rather than a clinical or scientific one. It works from cited reimbursement benchmarks, acquisition costs, work relative value unit values, disclosed transaction values and revenue figures, and reasons forward from rules that were proposed and not yet final at the time of writing. The report is explicit that those forward-looking sections are scenario analysis on proposed rules rather than settled outcomes, and that named companies and transactions are used to illustrate structural dynamics rather than to allege anything about their conduct. The factual cut-off is Q3 2026.
Written for radiopharma operators, institutional investors and capital allocators pricing radioligand therapy assets, and for the manufacturing and delivery networks whose economics depend on how these therapies are reimbursed.
Contents
- Parts I and II: the two clocks, and the inversion stated plainly
- Part III: the upstream toll-booth, rent on a decaying asset
- Part IV: the downstream billing mechanics
- Part V: reading the capital
- Part VI: reading the people
- Part VII: the two clocks together, arithmetic read forward
- Part VIII: the tripwires that resolve the thesis
- Part IX: where value, talent and capital should sit
Organisations and bodies referenced
Novartis, Telix, Bicycle Therapeutics, Ratio Therapeutics, Thor Medical, PanTera, Oncoinvent, NucliThera, RadioMedix, UK Nuclear Decommissioning Authority, Medicare
The full 27-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
The flagship radiopharma report is the paid companion to this briefing, covering the full sector structure, the operators, and the capacity picture the economics sit on top of.
See the full report →